The CEO and a number of key personnel acquires shares through the exercise of warrants in Intervacc's incentive program 2019/2022
Stockholm, July 26, 2022 - Intervacc AB (publ) (First North: IVACC) ("Intervacc") announces today that the CEO, Andreas Andersson, together with three other key persons, has subscribed for 330,455 shares through the utilization of the warrants issued under Intervacc's incentive program 2019/2022.
CEO Andreas Andersson and three other key persons have today utilized their opportunity to, through the exercise of warrants subscribe for shares in Intervacc's long-term incentive program 2019/2022 aimed at senior executives and other key persons. Within the incentive program, a total of 330,455 warrants have been issued, each of which entitles the holder to subscribe for one new share in Intervacc at a subscription price of SEK 18.52 per share.
To finance the subscription of share as well as cover personal tax effects, the warrant holders in the program, including the CEO, have sold a total of 165,226 shares. The sale was made off-market to institutional long-term investors.
Following the subscription of shares and sale in accordance with above, Andreas Andersson's shareholding in Intervacc will amount to 76,091 shares.
"I am very proud of the company's development and successes. Our first proprietary vaccine is approved for sale and marketing in the European Union and in the United Kingdom. We have strong partnerships in place and potential for further market approvals in several other markets as well as a strong and exciting project portfolio," says Andreas Andersson, CEO at Intervacc. "With our technology platform and vaccines, we have an opportunity to improve animal health and at the same time contribute to reducing the use of antibiotics. We are building an animal vaccine company with a global reach.”
With the above transactions, all warrants issued within the framework of the incentive program 2019/2022 have been utilized for subscription of shares and Intervacc thus receives approx. SEK 6 million in cash.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com
The information was submitted for publication, through the agency of the contact person set out above on July 26, 2022, 20.45 CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10
